ArticleBMC neurology2020
T2 mapping of molecular subtypes of WHO grade II/III gliomas.
Article in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- TNMR in biomedicine · 2026Article
- Comparison of ectopic versus normal gray matter via quantitative magnetic resonance imaging: a cross-sectional study.Quantitative imaging in medicine and surgery · 2025Article
- Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.European radiology experimental · 2025Article
- Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI.Frontiers in oncology · 2025Article
- Research Progress on Glioma Microenvironment and Invasiveness Utilizing Advanced Multi-Parametric Quantitative MRI.Cancers · 2024Review
- Article
- Whole-tumor histogram analysis of synthetic magnetic resonance imaging predicts isocitrate dehydrogenase mutation status in gliomas.Quantitative imaging in medicine and surgery · 2024Article
- Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures.Nature communications · 2023Article
- Advanced MR Techniques for Preoperative Glioma Characterization: Part 1.Journal of magnetic resonance imaging : JMRI · 2023Review
- Evaluation of Gliomas with Magnetic Resonance Fingerprinting with PET Correlation-A Comparative Study.Cancers · 2023Article
- Conventional MRI-Derived Biomarkers of Adult-Type Diffuse Glioma Molecular Subtypes: A Comprehensive Review.Biomedicines · 2022Review
- Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment.Magma (New York, N.Y.) · 2022Article
- T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.The neuroradiology journal · 2021Article
- Review
- Exploring diagnostic performance of T2 mapping in diffuse glioma grading.Quantitative imaging in medicine and surgery · 2021Article
- BET degrader inhibits tumor progression and stem-like cell growth via Wnt/β-catenin signaling repression in glioma cells.Cell death & disease · 2020Article
- Predicting methylation class from diffusely infiltrating adult gliomas using multimodality MRI data.Neuro-oncology advancesArticle
- Pitfalls in 2HG Detection With TE-Optimized MRS at 3T.Journal of neuroimaging : official journal of the American Society of NeuroimagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to the new WHO classification from 2016, molecular profiles have shown to provide reliable information about prognosis and treatment response. The purpose of our study is to evaluate the diagnostic potential of non-invasive quantitative T2 mapping in the detection of IDH1/2 mutation status in grade II-III gliomas.
methodsRetrospective evaluation of MR examinations in 30 patients with histopathological proven WHO-grade II (n = 9) and III (n = 21) astrocytomas (18 IDH-mutated, 12 IDH-wildtype). Consensus annotation by two observers by use of ROI's in quantitative T2-mapping sequences were performed in all patients. T2 relaxation times were measured pixelwise.
resultsA significant difference (p = 0,0037) between the central region of IDH-mutated tumors (356,83 ± 114,97 ms) and the IDH-wildtype (199,92 ± 53,13 ms) was found. Furthermore, relaxation times between the central region (322,62 ± 127,41 ms) and the peripheral region (211,1 ± 74,16 ms) of WHO grade II and III astrocytomas differed significantly (p = 0,0021). The central regions relaxation time of WHO-grade II (227,44 ± 80,09 ms) and III gliomas (322,62 ± 127,41 ms) did not differ significantly (p = 0,2276). The difference between the smallest and the largest T2 value (so called "range") is significantly larger (p = 0,0017) in IDH-mutated tumors (230,89 ± 121,11 ms) than in the IDH-wildtype (96,33 ± 101,46 ms). Interobserver variability showed no significant differences.
conclusionsQuantitative evaluation of T2-mapping relaxation times shows significant differences regarding the IDH-status in WHO grade II and III gliomas adding important information regarding the new 2016 World Health Organization (WHO) Classification of tumors of the central nervous system. This to our knowledge is the first study regarding T2 mapping and the IDH1/2 status shows that the mutational status seems to be more important for the appearance on T2 images than the WHO grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.